Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
At a glance
Social responsibility
Our companies
Business Model
Development capabilites
Partnering
Pipeline
Commercial Products
News & Events
Press Releases
Awards
Publications
Conferences
News
27.04.2010
Debiopharm Group™ starts Phase I clinical trial with Debio 0932
26.04.2010
Two New Tenants for EPFL’s Innovation Square
Home
News & Events
Press Releases
PRESS RELEASES
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
07-Sep-2009
Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent
< Prev
1
Next >
Results 1 - 1 of 1
Tremelimumab - codevelopment with Pfizer Inc
( 1 items )
Debio 0932
( 2 items )
Debio 0930
( 1 items )
Debio 0929
( 1 items )
Debio 0928
( 1 items )
Debio 0827
( 1 items )
Debio 0826
( 1 items )
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 14 items )
Debio 8609 Sanvar®
( 13 items )
Debio 025
( 9 items )
Debio 9902 - ZT-1
( 9 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0617
( 2 items )
Oxaliplatin – Eloxatin® – Elplat®
( 10 items )
Moapar® - Salvacyl®
( 5 items )
Other News
( 54 items )
